Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris <i>:</i> Results from a Phase 2 Trial-Reference-Cited by-同舟云学术

Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial

Published:2023-05-17 Issue:5 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Vazquez Jose A.¹,Pappas Peter G.²,Boffard Kenneth³,Paruk Fathima⁴,Bien Paul A.⁵,Tawadrous Margaret⁶^ORCID,Ople Eric⁵,Wedel Pamela⁵,Oborska Iwona⁵,Hodges Michael R.⁵

Affiliation:

1. Medical College of Georgia, Augusta University, Augusta, Georgia, USA

2. University of Alabama at Birmingham, Birmingham, Alabama, USA

3. Milpark Hospital, University of the Witwatersrand, Johannesburg, South Africa

4. Steve Biko Academic Hospital, University of Pretoria, Pretoria, South Africa

5. Amplyx Pharmaceuticals Inc., San Diego, California, USA

6. Pfizer Inc., Groton, Connecticut, USA

Abstract

Fosmanogepix (FMGX), a novel antifungal available in intravenous (IV) and oral formulations, has broad-spectrum activity against pathogenic yeasts and molds, including fungi resistant to standard of care antifungals. This multicenter, open-label, single-arm study evaluated FMGX safety and efficacy for treatment of candidemia and/or invasive candidiasis caused by Candida auris .

Funder

Amplyx

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01419-22

Reference37 articles.

1. Multidrug-ResistantCandida haemuloniiandC. auris, Tel Aviv, Israel

2. Tracing the Evolutionary History and Global Expansion of Candida auris Using Population Genomic Analyses

3. Candida auris–Associated Candidemia, South Africa